• To examine the current EU5 market access landscape for ATMPs.
Objec ves
• To examine the current EU5 market access landscape for ATMPs.
• Examined all ATMPs from Chondrocelect which was the fi rst approved ATMP by the European Commission (EC) in October 2009 to Zalmoxis recently approved in September 2016
• Reviewed market access status of ATMPs across the EU5 based on lis ngs in na onal price databases and assessment from na onal HTA agencies such as the HAS (France), GBA (Germany), AIFA (Italy) and NICE/SMC (UK)
• Examined me to market for all ATMPs across the EU5
Methods (cont'd)

Methods
• Assessed the regulatory path, HTA assessments and funding mechanisms for ATMPs
Results
• Eight ATMPs have been approved by the EC as of September 2016 (Table 1a and Table 1b) -Germany has a dual regulatory requirement as authoriza on needed from Paul Ehrlich Ins tute (PEI)
• Of the approved ATMPs, two are no longer available and the third will be withdrawn later this year -Market authoriza on was suspended for MACI (matrix-induced autologous chondrocyte implanta on) based on CHMP recommenda on -Market authoriza on was withdrawn for Provenge (sipuleucel-T) upon the request of the marke ng authoriza on holder -Market authoriza on will be withdrawn for Chondrocelect (characterised viable autologous car lage cells expanded ex vivo expressing specifi c marker proteins) as of November 30, 2016 for commercial reasons
• Glybera (alipogene parvovec), the fi rst gene therapy to be approved by the EC (2012), a hospital use only drug in Germany with reimbursement nego ated by the hospital and sickness funds on a case by case basis, is not reimbursed in any of the other EU4 markets -Ex-factory cost of treatment is €984,000 (Germany) and £693,000 in the UK (70kg pa ent, 24 vials used)
• Holoclar (Ex vivo expanded autologous human corneal epithelial cells containing stem cells), a more recent approval (2016), is an interes ng case study of an ATMP that has been classifi ed as a procedure by the GBA in Germany and therefore bypassed AMNOG assessment -It is not yet marketed/commercialized in the other EU4 markets where nego a ons are ongoing
• Imlygic (talimogene laherparepvec), is the only ATMP assessed and recommended for use in the UK by NICE under a PAS -Not reviewed by the SMC (none of the ATMPs on the market have been reviewed by SMC as of September 2016)
• Strimvelis (autologous CD34+ cells transduced to express ADA) is a unique case in terms of pricing (only one price, valid wherever the pa ents come from) and reimbursement (payment by results and payment by instalments in Italy, with other countries likely to nego ate similar condi ons) and could represent a new model for ATMPs • Zalmoxis (gene cally modifi ed allogeneic T cells) is the latest ATMP approved by the EMA but is not yet commercially available in any EU country
Conclusions
• Although the fi rst ATMP was approved 8 years ago, the PRMA landscape is s ll forming and evolving -Three of the eight approved therapies have been withdrawn; although it could be argued that these treatments were launched in areas where other therapeu c op ons were available • All EMA approved ATMPs to date have faced EU5 access challenges, with Germany being par cularly complex -HTA assessments have been unfavourable largely due to the uncertainty with available data andpossibly -costs • There is a contradic on in terms of incen ves that exist on the regulatory side for faster development of ATMPs (e.g. 6 ATMPs under PRIME program) versus the stark market access challenges with payers reluctance to reimburse these therapies
• Reimbursement paths need to solidify for AMTPs to be viable for the companies seeking to market them and the pa ents who will benefi t • Given the increased pace in submissions of new ATMPs, new models may be needed to address P&R issues especially for therapies that address a true unmet need -Strimvelis may be the fi rst example of an ATMP following the path of innova ve P&R mechanism already tried in other areas like oncology/orphan but with the uniqueness of having one exfactory price set across the EU and a payment by instalment model nego ated at least with Italian authori es 
